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PLATELETS AND THROMBOPOIESIS
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Key Points
• The Optimul 96-well platelet
aggregation assay has high
levels of sensitivity and
specificity for detecting
platelet defects.
• The requirement for
a small volume of blood,
straightforward nature,
and speed make Optimul
a promising screening test
in bleeding patients.
Up to 1% of the population have mild bleeding disorders, but these remain poorly
characterized, particularly with regard to the roles of platelets. We have compared the
usefulness of Optimul, a 96-well plate-based assay of 7 distinct pathways of platelet
activation to characterize inheritedplatelet defects in comparisonwith light transmission
aggregometry (LTA). Using Optimul and LTA, concentration-response curves were gen-
erated for arachidonic acid, ADP, collagen, epinephrine, Thrombin receptor activating-
peptide, U46619, and ristocetin in samples from (1) healthy volunteers (n5 50), (2) healthy
volunteers treatedwith antiplatelet agents in vitro (n5 10), and (3) patientswith bleedingof
unknown origin (n 5 65). The assays gave concordant results in 82% of cases (k 5 0.62,
P < .0001). Normal platelet function results were particularly predictive (sensitivity, 94%;
negative predictive value, 91%), whereas a positive result was not always substantiated by
LTA (specificity, 67%; positive predictive value, 77%). TheOptimul assay was significantly
moresensitive at characterizingdefects in the thromboxanepathway,whichpresentedwith
normal responseswithLTA.TheOptimulassay issensitive tomildplateletdefects, couldbe
used as a rapid screening assay in patients presenting with bleeding symptoms, and
detects changes in platelet function more readily than LTA. This trial was registered at www.isrctn.org as #ISRCTN 77951167. (Blood.
2014;123(8):e11-e22)
Introduction
Mild bleeding disorders are prevalent in the general population with
a frequency of up to 1%.1 Nonetheless, they often remain poorly
characterized, both in termsof clinical and laboratory-baseddiagnosis.1
This stems in part from the fact that excessive bleeding only manifests
in some patients in response to an appropriate challenge such as
surgery, trauma, menstruation, and childbirth, and in part because the
laboratory measures of platelet dysfunction, including the current gold
standard light transmission aggregometry (LTA), require specialized
expertise and are time-consuming.2 The recognition that bleeding is
a multifactorial and complex process has fueled the search for platelet
function assays that have the ability to assess a whole spectrum of
platelet responses, require a small volume of blood, and require
minimal technical expertise.2-4
Several attempts at developing a high-throughput platelet function
assay are currently being investigated. These include devices that
measure global platelet reactivity in response to shear alone,5 micro-
ﬂuidic devices with precoated adhesion or activation molecules,6-8
assays that measure calcium ﬂux in platelets by ﬂuorescent imaging,9
enzyme-linked immunosorbent assay–type assays to capture platelets
on agonist-coated surfaces,10 luminometric assays of platelet secre-
tion in response to various platelet agonists,11 and ﬂow cytometric
counting techniques with platelet immunostaining.12 Most of these
techniques require specialized laboratory instruments (ﬂow cytom-
eters, osmotic pumps, microscopes, imaging devices) or can be ex-
pensive to perform (single use precoated cartridges or capillaries,
ﬂuorescent antibodies), and not all are sensitive to mild platelet
inhibition,10 making them unsuitable for use in nonspecialized
centers.
The development of the Optimul assay with lyophilized reagents
on a standard half-area 96-well microtiter plate may provide a more
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cost-effective alternative for high-throughput platelet function testing.13
The assay requires a plate heater/shaker and an absorbance plate reader,
which are available in most clinical and research laboratories.13 The
Optimul assay is carried out on 2.5 mL of platelet-rich plasma (PRP),
takes 10 minutes to perform and analyze, and provides full dose-
response curves to 7 commonly used platelet agonists.13,14
We sought to investigate how the Optimul assay compares with
the gold standard in platelet function testing, lumi-aggregomery, and
whether it could be used to diagnose platelet defects in patients
presenting with bleeding symptoms suggestive of inherited platelet
function defects.
Material and methods
Participant selection
Healthy volunteers. Participants were considered healthy if they were$18
years of age, did not require long-term medical therapy, had refrained from
drugs known to inﬂuence platelet function in the previous 2 weeks, and did
not have a history of bleeding symptoms.
Patients suffering from bleeding diathesis. Participants with sus-
pected inherited platelet function defects were recruited to the Genotyping and
Phenotyping of Platelets study (GAPP; ISRCTN 77951167) from November
2011 to December 2012 from UK Comprehensive Care Haemophilia Centers
and were invited to participate in this study if they satisﬁed all the following
inclusion criteria: (1) abnormal bleeding symptoms compatible with a platelet
function defect (spontaneous mucocutaneous bleeding or abnormal bleeding at
other sites following trauma or invasive procedures); (2) results from coag-
ulation factor tests within local laboratory reference intervals (minimum panel
of prothrombin time, activated thromboplastin time, Clauss ﬁbrinogen activity,
von Willebrand proﬁle); and (3) absence of demonstrable acquired platelet
dysfunction. Patients with existing diagnoses of Glanzmann’s thrombasthe-
nia, Bernard-Soulier syndrome, Hermansky Pudlak syndrome, or MYH9-
related disorder were excluded. Participants with platelet counts outside the
150 to 450 3 109/L range were excluded. Laboratory testing was deferred
in participants exposed within 2 weeks to drugs known to affect platelet
function.
This study was approved by the National Research Ethics Service
Committee West Midlands–Edgbaston (REC reference: 06/MRE07/36), and
all participants gave written informed consent. This study was conducted in
accordance with the Declaration of Helsinki.
Assessment of platelet function
Blood was drawn by venipuncture into evacuated tubes containing 3.1%
trisodiumcitrate (S-Monovette 0.106M;Sarstedt, Leicester,UnitedKingdom
[UK], in line with the latest expert consensus documents.15 PRPwas prepared
by centrifugation of whole blood at 200g for 20minutes. Platelet-poor plasma
(PPP) was prepared by centrifugation of the remaining blood at 1000g for 10
minutes.
To assess the effect of antiplatelet drugs in vitro, in some experiments,
sampleswere pretreatedwith 100mMaspirin (Sigma-Aldrich, Dorset, UK) or
1 mM cangrelor (The Medicines Company, Abingdon, UK) prior to platelet
function testing.
LTA. Platelet function was assessed using LTA as described pre-
viously.16 Platelet aggregation was measured in PRP using a dual Chronolog
lumiaggregometer (Model 460 VS; Havertown, PA) in response to ADP
(Sigma-Aldrich, Poole, UK); epinephrine (Sigma-Aldrich, Poole, UK);
arachidonic acid (AA; Cayman Chemical, Cambridge Bioscience Ltd.);
PAR-1 receptor-speciﬁc peptide (SFLLRN; Alta Biosciences, Birming-
ham, UK), collagen (Nycomed, Linz, Austria); and ristocetin (Helena Bio-
sciences, Sunderland, UK). ATP secretion was assessed using the Luciferin-
Luciferase reagent (Chronolume) and an ATP standard solution. Results were
classiﬁed as abnormal by reference to a bank of local healthy volunteers
(presented in supplemental Figure 1 and supplemental Table 1, available on
the Blood Web site).
Optimul assay. Optimul 96-well plates were prepared as previously
described.13 Brieﬂy, ﬂat-bottom half-area microtiter plates (Greiner Bio-
One; Stonehouse, Gloucestershire, UK) were precoated with hydrogenated
gelatin (0.75% weight/volume, Sigma-Aldrich, Poole, UK) in phosphate-
buffered saline (Sigma-Aldrich, Poole, UK) to block the surface activation
of platelets before the addition of platelet agonists. The agonists used were
AA (0.03-1 mM; Sigma-Aldrich, Poole, UK), ADP (0.005-40 mM; Sigma-
Aldrich, Poole, UK), epinephrine (0.0004-10 mM; Labmedics, Stockport,
UK), collagen (0.01-40 mg/mL; Nycomed, Linz, Austria), TRAP-6 amide
(SFLLRN; 0.03-40 mM, Bachem, St. Helens, UK), U46619 (0.005-40 mM;
Labmedics, Stockport, UK), and ristocetin (0.14-4 mg/mL; Helena
Biosciences, Tyne and Wear, UK). The agonists were lyophilized by
placing the plates in a280°C freezer for 1 hour and transferring into a freeze-
dryer overnight at 240°C. The plates were then removed from the freeze-
dryer, vacuum-sealed, foil-packed, and kept at room temperature until use
within 12 weeks of manufacture.
PRP or PPP (40 mL) was added into the appropriate agonist-free control
wells of the 96-well plate. PRP was then added to the agonist-coated wells
with a multi-channel pipette. The plate was sealed with ﬁlm and placed on
a heater/shaker (BioShake iQ; Q Instruments, Jena, Germany) at 37°C to mix
at 1200 rpm for 5minutes. Absorbancewas thenmeasured at 595 nm on a 96-
well plate reader (VersaMax Microplate reader; Associates of Cape Cod Inc.,
East Falmouth,MA). Platelet aggregationwas expressed as themaximalpercent
change in light transmittance fromPRPwells in response to agonists, using PPP
wells as reference. Optimization and characterization of theOptimul assay have
been previously reported.13,14,17
AnOptimul panelwas deﬁned as abnormal if the dose-response curvewas
below the lower limit of the 95% reference interval for.1 agonist.
Plasma thromboxane B2. After aggregation, indomethacin (30 mM)
was added in relevantwells to stop cyclooxygenase (COX) activity. Thewhole
platewas then centrifuged (1300g for 10minutes) at room temperature, and the
supernatantswere collectedand frozen at280°C.Plasma thromboxane (Tx)B2
levels, a measure of TxA2 formation, were determined by a competitive im-
munoassay (in-house homogeneous time resolved ﬂuorescence assay, de-
veloped with assistance of Cisbio Bioassays, Codolet, France).
Statistical analyses
Normally distributed continuous variables are presented as mean6 standard
deviation, non-normally distributed continuous variables as median (inter-
quartile range), and categorical variables as frequencies (percentages). Variables
were analyzed for a normal distribution with the Kolmogorov-Smirnov test.
Concentration-response curves were generated using a 4-parameter log-linear
function in GraphPad Prism Software 5 for Windows (GraphPad Software, San
Diego, CA). The area under the curve (AUC) analysis was carried out for each
individual curve generated. For comparison of assays where the tests were
performed by both assays on the same blood samples, paired analyseswere used.
Agreement in the classiﬁcation of platelet defects between the 2 assays was
assessed by the k statistic. Analyses were performedwith Statistical Package for
the Social Sciences (SPSS) 14.0 for Windows (SPSS Institute).
Results
Optimul performance characteristics in healthy volunteers
Platelet function was assessed in 50 healthy volunteers (aged 336 7
years, 38%men); in 10 of these, platelet function testing was repeated
2weeks later to assess intraindividual variability.As shown inFigure 1
and supplemental Table 2, with all agonists used in theOptimul assay,
platelets displayed a dose-response relationship that was similar to that
observed with LTA and was reproducible within subjects with repeat
testing of blood sample obtained at different venepunctures. Therewas
no association between the extent of platelet aggregation and either
platelet count inPRPormean platelet volume (supplemental Figure 2).
We observed greater variability between healthy donor subjects in the
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Optimul test results compared with LTA test results at intermediate
concentrations of AA and collagen (Figure 2). Because platelet
aggregation responses to both collagen and AA are sensitive to
defectivemetabolismofAA intoTxA2,we investigated this difference
further by measuring concentrations of TxB2 (a marker of TxA2
synthesis) in a subset of healthy volunteers (n 5 25). This dem-
onstrated that most healthy controls who displayed reduced ag-
gregation responses by Optimul to AA and collagen also showed
reduced TxB2 production (Figure 3), indicating that this group had
impaired AA metabolism, most likely as a result of inadvertent non-
steroidal anti-inﬂammatory drug ingestion. Our observation that this
group displayed normal LTA results with AA and collagen suggests
that theOptimul offers greater sensitivity to defects in AAmetabolism
than LTA.
Effect of antiplatelet agents
To assess the performance of theOptimul assay in detecting the effect
of antiplatelet therapy, PRP samples obtained from 10 healthy vol-
unteers were treated in vitro with 100 mM aspirin to assess COX
inhibition or 1 mM cangrelor to assess P2Y12 receptor inhibition. As
shown in Figure 4, both LTA and Optimul detected inhibition of
platelet function by in vitro addition of antiplatelet agents, withOptimul
being signiﬁcantly more sensitive than LTA and displaying marked
Figure 1. Reference intervals for the Optimul assay. (A) Dose-response curves in 50 healthy volunteers, presented as median and interquartile range. (B) Repeat testing in 10
healthy volunteers, presented as median and interquartile range. Open squares represent the first test, and closed squares represent repeat testing in the same individuals.
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impairment in multiple platelet activation pathways, consistent with
the role of TxA2 andADPas amplifying signals for other agonists.
18,19
Receiver-operator characteristic (ROC) curve analysis is presented in
supplemental Figure 3, showing how the distribution of healthy donor
response overlaps with healthy donor response treated with anti-
platelet agents. Both lumi-aggregometry and theOptimul assay had
high levels of discrimination, withOptimul achieving higher levels
of AUC for multiple agonists (supplemental Figure 3). Most notably,
inhibition of the P2Y12 receptor resulted in marked inhibition of AA-
and collagen-induced platelet responses onOptimul that was not seen
with LTA, highlighting the reliance of theOptimul assay on adequate
ADP receptor activity as an amplifying signal leading to sustained
platelet aggregation to these 2 agonists (Figure 4). Inhibition of COXby
aspirin induced a less severe phenotype of platelet responses, with only
AA- and collagen-induced aggregation being signiﬁcantly affected
(Figure 4).
Investigation of patients with a suspected impairment in
platelet function
We sought to investigate whether the Optimul assay could be used
to detect platelet defects in patients with a suspected inherited
impairment in platelet function. Patients with suspected inherited
platelet function defects (n5 65, aged 386 19 years, 25%male) were
recruited to the GAPP study from UK Comprehensive Care
Haemophilia Centers. Participants had a lifelong bleeding history as
demonstrated by their elevated ISTHBleedingAssessment Tool score
(median, 10; interquartile range, 7-15; 95th percentile in healthy
volunteers was 4).20,21
Figure 2. Agreement between LTA and the Optimul assay in healthy volunteers. Individual data for top concentrations of the agonists studied with LTA and within
a similar range on Optimul: AA, 1 mM (LTA) to 1 mM (Optimul); ADP, 30-40 mM; collagen, 3 mg/mL to 2.5 mg/mL; epinephrine, 10 mM to 10 mM; TRAP, 100 mM peptide to
40 mM amide; U46619, 10 mM to 8.9 mM; ristocetin, 1.5 mg/mL to 1.3 mg/mL.
Figure 3. TxB2 concentration in plasma super-
natants from healthy volunteers and patients with
bleeding symptoms. TxB2 concentration adjusted
for platelet count in healthy volunteers with normal
(n 5 20) or impaired (n 5 5) AA response on Optimul
and in patients with bleeding disorders with normal
(n 5 18) or impaired (n 5 17) AA response on Optimul.
Line and whiskers represent median and interquartile
range; the gray band represents the normal range
derived from bank of healthy volunteers.
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A platelet defect was found in 54% of participants with bleeding
symptoms on LTA and in 66%with theOptimul assay (Table 1). The
participants’ bleeding history was not predictive of a platelet func-
tion defect identiﬁed by either LTAor theOptimul assay (Figure 5).21
The assays gave concordant results in 82% of cases (k 5 0.62,
P , .0001), suggesting substantial agreement between assays. A
normal platelet function result detected by Optimul testing was
particularly predictive (sensitivity, 94%; negative predictive value,
91%) of a normal result by reference standard LTA testing. Strikingly,
the dose-response curves of patients with bleeding symptoms but
in whom no platelet defect was found by lumi-aggregometry were
superimposable on the dose-response curves obtained from healthy
volunteers (Figure 6), further supporting the high negative predictive
value of this assay. This was in line with ROC curve analyses with
AUCs not signiﬁcantly different from 0.5 (supplemental Figure 4A).
By contrast, an abnormal platelet function test was detected by
Optimul testing in 10 of 65 subjects with suspected platelet func-
tion disorders who displayed normal LTA test results. Of the 10
patients with discordant results onOptimul, 7 had impaired collagen
responses either in isolation or associated with impairments in other
pathways; 1 had a Gi-type presentation; 1 had isolated impairment in
AA responses; and 1 had isolated impairment in TRAP responses.
Figure 4. Effect of antiplatelet agents added in vitro to samples from healthy volunteers on maximal platelet aggregation. (A) Dose-response curves obtained with
Optimul in 10 healthy volunteers, presented as median and interquartile range. Open squares represent nontreated samples, the red triangles represent aspirin 100 mM–treated
samples, and the green circles represent cangrelor 1 mM–treated samples in the same individuals. (B) Dose-response curves obtained with LTA in 10 healthy volunteers,
presented as median and interquartile range. Open squares represent nontreated samples, the red triangles represent aspirin 100 mM–treated samples, and the green
circles represent cangrelor 1 mM–treated samples in the same individuals.
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The molecular signiﬁcance of this is unknown, in view of the dis-
crepant results with gold standard lumi-aggregometry and the
positive bleeding history suggestive of a platelet defect. Accord-
ingly, Optimul testing showed lower speciﬁcity (67%) and positive
predictive value (77%) for platelet function disorders compared
with the reference standard LTA test. It is not possible to distinguish
in this analysis whether this ﬁnding indicates a true reduction in
Optimul test speciﬁcity or whether the Optimul test offers greater
sensitivity for the detection of platelet function disorders than LTA.
Patterns of response in patients with platelet defects
The patients in whom a platelet defect was found by LTA were
further subdivided into categories, as recently described by our
group.16 The pattern of platelet responses obtained with the Optimul
assay for each type of defect based on lumi-aggregometry is shown in
Figure 6. ROC curve analyses are presented in supplemental
Figure 4B-D.
A secretion defect (deﬁned on lumi-aggregometry as dense
granule secretion ,5th percentile of normal response to 100 mM
TRAP peptide, n5 14 [22%]) was apparent on the Optimul assay as
a rightward shift in dose-response in response to most agonists
(Figure 6A), except ADP (which adds excess ADP and is relatively
insensitive to secretion defects), and ristocetin (which relies on passive
agglutination of platelets and does not require platelet activation). It
follows that the AUC for all agonists, with the exception of ADP and
ristocetin, was signiﬁcantly lower in patients with secretion defects
(Figure 6D and supplemental Figure 4B).
A defect in the thromboxane pathway (deﬁned as either impaired
thromboxane generation or thromboxane receptor activity, n 5 4
[6%]) appears as a lack of response to AA, accompanied by a sig-
niﬁcant shift in response to collagen, which strongly relies on
thromboxane generation as a secondary mediator (Figure 6B). The
thromboxane mimetic (U46619) response can be impaired if there is
a defect in the thromboxane receptor, but preserved if there is a defect
in the COX enzyme leading to abnormal thromboxane generation.
Accordingly, the AUC for these agonistswere signiﬁcantly reduced in
comparison with healthy volunteers or patients without a platelet
defect (Figure 6D and supplemental Figure 4C).
Finally, a Gi-type defect (deﬁned as a defect in aggregation and
secretion to the 2 Gi-coupled receptor agonists ADP and epinephrine,
n 5 12 [18%]) was the most heterogeneous presentation on Optimul
(Figure 6C). Whereas the dose-response curve to epinephrine was
systematically impaired, the level of inhibition of the other ag-
onists was signiﬁcantly more variable with minor rightward shifts
in dose-response curves, which nonetheless translated into sig-
niﬁcant differences on AUC (Figure 6D and supplemental
Figure 4D).
Because most platelet defects presented as impairments in AA-
induced aggregation, further investigationwas undertaken into TxA2
generation in a subset of patients with bleeding symptoms of
unknown etiology (n 5 35; n 5 17 with abnormal AA response on
Optimul). Interestingly, although in some participants TxB2 con-
centration suggested impaired COX activity, in most participants
TxB2 concentration fell within ranges compatible with normal COX
function (Figure 3), thus shifting the interpretation toward a defect
in dense granule/ADP-dependent ampliﬁcation pathways.
Phenotype-genotype associations
To determine whether theOptimul assay could detect known platelet
defects in the main platelet activation pathways, analysis was
undertaken in patientswith platelet function defects inwhom speciﬁc
mutations had been identiﬁed within the GAPP study.
Lumi-aggregometry suggestive of a defect in the thromboxane
receptor had led to genotyping of the TBXA2R gene in a participant
with a severe bleeding history. A novel heterozygous mutation was
found translating into an asparagine to serine change at position 42.
Thismutation prevents agonist activation of the receptor as a result of
poor expression at the cell surface membrane.22 The participant’s
Table 1. Distribution of platelet defects in patients with bleeding symptoms suggestive of a platelet defect
Concordant in 82% of cases; k 5 0.62, P , .0001, positive likelihood ratio 5 sensitivity/(1 2 specificity) 5 2.83, negative likelihood ratio 5 (1 2 sensitivity)/
specificity 5 0.09.
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Optimul results are shown in Figure 7A and conﬁrmed a marked
impairment of AA-induced aggregation with a profound rightward
shift in response to the thromboxane mimetic U46619, whereas
responses to other agonists were unaltered. Measurement of TxB2 on
the highest concentration of the AA-induced aggregation on the
Optimul plate demonstrated normal TxA2 generation, despite absence
of an aggregation response to AA (40.7 ng/L3 108 platelets; normal
range, 19.1-157.6 ng/L3 108 platelets), conﬁrming the defect was at
the level of the receptor and not in the enzymatic conversion of AA
into TxA2.
Lumi-aggregometry suggestive of a defect in the ADP P2Y12
receptor had led to the identiﬁcation of a novel heterozygous
mutation predicting an arginine to histidine change at position 122.
This mutation maps to the DRYmotif, a highly conserved region in
G-coupled receptors, which was shown in expression studies to
inhibit platelet activation by ADP.23,24 Representative Optimul
traces from this family are shown in Figure 7B. Impairment in all
platelet pathways (except for passive agglutination onto ristocetin)
was consistent with a platelet activation defect and was seen in
all family members. Further investigation into TxA2 generation
conﬁrmed normal COX activity in all family members and reinforced
the likelihood that the defect was due to lack of ampliﬁcation by
ADP, with reduced ADP responses suggestive of a defect in ADP
receptors.
Discussion
The main ﬁndings of this study are as follows: (1) the Optimul assay
was robust and reproducible, was completed in a much shorter time
after preparation of PRP (10 minutes vs 2 hours) and required sig-
niﬁcantly less blood than traditional LTA testing (6 vs 50mL); (2) both
assays detected platelet inhibition induced by commonly used
antiplatelet agents in samples from healthy volunteers treated with
antiplatelets in vitro; (3) both assays detected platelet defects in
patients presenting with bleeding symptoms suggestive of a platelet
function disorder; (4) Optimul offers high sensitivity for platelet
function disorders identiﬁed by the reference standard of LTA
testing; and (5) Optimul showed lower speciﬁcity for platelet
function disorders deﬁned by LTA. However, the greater sensitivity
of Optimul to platelet inhibition by antiplatelet drugs may suggest
that this reﬂects an inability of LTA to identify some subtle platelet
function disorders. The higher sensitivity of the Optimul assay to
platelet inhibition and the more global portrait of platelet reactivity
to a wider range of agonists and agonist concentrations make it
particularly appealing for investigation of platelet phenotypes asso-
ciated with the complex process of bleeding.
Utility of platelet function testing in mild bleeding disorders
Inherited platelet function disorders are a heterogeneous group of
defects, which include defects in platelet receptor function, enzyma-
tic activity, trafﬁcking and granule secretion, and procoagulant
activity.1,25 Despite this variety in the molecular basis of the disorder,
patients present with a common mucocutaneous bleeding phenotype,
which is difﬁcult to distinguish fromothermore commonmild bleeding
disorders, for example von Willebrand’s disease.1,25,26 The situation is
further complicated by the fact thatmucocutaneous bleeding symptoms
are reported in a signiﬁcant proportion of the healthy population,
leading to difﬁculties in determining what level of bleeding is to be
considered pathological.27 Laboratory investigation of individuals with
bleeding symptoms has thus far suffered from the absence of a test that
could monitor a whole spectrum of platelet responses and require
a small volume of blood and little technical expertise.4,26 As
a consequence, inherited platelet disorders remain underdiagnosed,
and under-researched.
We and others have previously shown LTA combined with ATP
secretion assessment to be a valuable diagnostic tool.16,28-30 Further-
more, the latest guidelines recommend the use of lumi-aggregometry
in the aid to diagnosing inherited platelet defects.26 However,
there are wide variations between laboratories using lumi-
aggregometry for platelet function testing, which results in lack
of standardization.31-33 Moreover, lumi-aggregometry requires spe-
ciﬁc expertise, both in its performance and its interpretation;
expensive machinery; a large volume of blood; and is time and labor
intensive.4,30 The latest expert consensus document outlines a number
of preanalytical, methodological, and interpretation variables that
inﬂuence platelet aggregation results.15 Extensive expertise is required
in the interpretation of aggregation traces, which should include
evaluation of shape change, length of lag phase, slope of aggregation,
amplitude of aggregation, deaggregation, and visual examination of
each individual trace, making the exercise dependent on the
experience of the observer.15 Differences in performance of LTA
and interpretation of tracings result in even the best diagnostic
laboratories worldwide ﬁnding the application of lumi-aggregometry
to large groups of patients challenging.31-33 In an effort to standardize
and streamline the process,we previously suggested a rationalized and
Figure 5. Association between presence of a platelet function defect and the
ISTH bleeding assessment tool score. Ninety-fifth percentile (score of 4) calculated
fromhealthy volunteers and representedby horizontal dotted line.The line represents the
median and thewhiskers represent the interquartile range. (A) Presence and absence of
a platelet defect defined by lumi-aggregometry. (B) Presence and absence of a platelet
defect defined by the Optimul assay.
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concise panel of agonists to be used with lumi-aggregometry and
showed this to be clinically equivalent to using an extensive aggre-
gation panel.16 Nonetheless, the requirement for blood volume and
time remains a challenge, especially in circumstances where a large
blood volume is difﬁcult to obtain, eg, in children, or in a high-
throughput setting such as screening for defects in all-comers with
bleeding symptoms. Thus, a high-throughput assay that couldmonitor
a whole spectrum of platelet responses and would require a small
volume of blood and little technical expertise would be clinically
useful.
Because the Optimul assay is based on light absorbance through
a stirred PRP sample, a methodology similar to that used in
traditional LTA, we sought to directly compare the methodologies
in their efﬁcacy to measure platelet function. The differences in
sensitivity to platelet inhibition by these 2 assays serves to stress that
despite similarities in the way platelet aggregation is measured
between conventional LTA andOptimul, the dynamic forces involved
due to either the smaller volumes of PRP used or the different shaking
method are sufﬁcient tomodify platelet behavior. It is also important to
note that theOptimul assay is an end point assay; thus, the increase in
Figure 6. Pattern of platelet responses obtained with Optimul. (A) Dose-response curves presented as median and interquartile range. Open squares represent healthy
volunteers, the striped squares represent patients with bleeding symptoms in whom no defect was found on LTA, and red lozenges represent patients in whom a secretion defect
was found on LTA. (B) Dose-response curves presented as median and interquartile range. Open squares represent healthy volunteers, the striped squares represent patients
with bleeding symptoms in whom no defect was found on LTA, and green circles represent patients in whom a thromboxane pathway defect was found on LTA. (C) Dose-
response curves presented as median and interquartile range. Open squares represent healthy volunteers, the striped squares represent patients with bleeding symptoms in
whom no defect was found on LTA, and blue triangles represent patients in whom a Gi-type defect was found on LTA. (D) Summary of finding presented as AUC for each of the
types of platelet phenotypes defined by LTA. Data presented as median and interquartile range; the whiskers represent the 5th and 95th percentiles.
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throughput is at the expense of the kinetic information available with
LTA. Whereas aggregation at 5 minutes incorporates elements of lag
phase, maximal amplitude, and deaggregation, visual inspection of
the time-dependent nature of aggregation with shape change and
primary and secondary wave of aggregation is not available with the
Optimul assay.
Potential application of the Optimul assay for platelet
function screening
There is increasing demand on physicians for complete information,
which partly stems from the desire of patients to avoid unnecessary
and predictable complications and to better characterize and under-
stand their symptoms.34 In the context of inherited bleeding dis-
orders, availability of drugs and devices that protect at-risk patients
from bleeding complications (eg, desmopressin or antiﬁbrinolytics)
renders the diagnosis of a bleeding diathesis clinically relevant.35,36
The Optimul assay could be used as an initial screening assay in
patients presenting with bleeding symptoms to direct further in-
vestigation, and reduce the time, blood, and labor intensity compared
with standard lumi-aggregometry practices. Notwithstanding, the
majority of the participants included within GAPP do not present
with striking laboratory phenotypes that map to a single platelet
activation pathway.1 This ﬁnding thus opens up the ﬁeld of whole-
exome genotyping, with the aim of discovering novel mutations to
account for the participants’ bleeding and platelet phenotypes. In this
setting, the negative discriminative power is crucial to select only
those participants with a strong indication for a platelet defect. The
Optimul assay used in this fashion could allow high-throughput
screening.
From a clinical perspective, the treatment of patients with
a platelet defect does not rely on the underlying molecular
mechanisms, and thus the demonstration of a clear platelet defect
is more clinically valuable than the demonstration of a defect in
a speciﬁc platelet pathway.34 The application of a high-throughput
highly sensitive assay could thus allow for more widespread use
of platelet function testing to aid in diagnosis of inherited platelet
defects. The ease of use, speed, small blood requirement, and
no need for specialized equipment for the performance of the
Optimul assay render it particularly appealing, especially outside
of large tertiary centers, and could help alleviate the burden of
platelet function testing in patients presenting with bleeding. Its
use in this context, however, requires large clinical studies to be
carried out.
Figure 6. (Continued).
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Conclusion
This study demonstrates that theOptimul assay, which exploits the
advantages of the 96-well plate format, is useful in characterizing
platelet function in healthy volunteers and in patients presenting
with bleeding suggestive of an inherited platelet function defect. It
offers distinct advantages in terms of being faster, requiring less
blood, and allowing AUCs to be determined, but the tradeoffs
include greater complexity until a commercial equivalent can be
devised and the loss of kinetic information. Applying this assay to
the 65 participants in this study as a screening assay could
have avoided detailed phenotyping with lumi-aggregometry in
22 participants (34%) and would have correctly identiﬁed 33
participants (51%) as having a platelet defect. This beneﬁt would
have occurred at the cost of 2 missed diagnoses of platelet defects
and 10 extra diagnoses that were later not substantiated by lumi-
aggregometry. In a clinical setting, the high negative predictive
value of the Optimul assay makes it particularly appealing as
a screening assay in nonspecialized centers. Indeed, its use could
prevent extra platelet function testing in up to a third of patients
Figure 7. Platelet responses obtained with Optimul in patients with known mutations. (A) Patient with a mutation in the TP receptor. (B) Patient with a mutation in the
P2Y12 receptor. Dose-response curves presented as median and interquartile range. Open squares represent healthy volunteers, and the black triangles represent the
participant with a thromboxane receptor mutation in A and a P2Y12 receptor mutation in B.
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with excessive bleeding and could select the remaining patients to be
referred on for more detailed phenotyping in a specialized center.
Although this assay is not quite yet a “lab on a chip,” it provides
amultifaceted portrait of platelet function that is frequently lacking in
current platelet function assays. Future studies are needed to explore
whether the Optimul assay used as an initial screening tool, in
conjunction with a rationalized LTA panel, may be useful in patients
with a clinical history of mild bleeding to identify hidden genetic
hemostatic defects, which often go unnoticed until a challenge, such
as surgery or addition of an antiplatelet agent, unveils the underlying
defect.
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